Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vir BiotechnologyVIR +0.96% Return-on-Tangible-Equity is 36.69% as of Jun. 2026. The stock has 5 warning signs investors should review. Among 1,198 Biotechnology companies, Vir Biotechnology ranks better than 57.51% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vir Biotechnology's annualized net income for the quarter that ended in Jun. 2026 was $320.3 Mil. Vir Biotechnology's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $873.0 Mil. Therefore, Vir Biotechnology's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 36.69%.
The historical rank and industry rank for Vir Biotechnology's Return-on-Tangible-Equity or its related term are showing as below:
VIR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -252.59 Med: -39.01 Max: 51.63
Current: -30.1
During the past 9 years, Vir Biotechnology's highest Return-on-Tangible-Equity was 51.63%. The lowest was -252.59%. And the median was -39.01%.
VIR's Return-on-Tangible-Equity is ranked better than 57.51% of 1198
companies
in the Biotechnology industry
Industry Median: -42.355
vs VIR: -30.10
Vir Biotechnology (NAS:VIR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vir Biotechnology Return-on-Tangible-Equity Related Terms
Vir Biotechnology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIR vs AVBP, XNCR, SEPN: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Vir Biotechnology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 36.69% mean?
Vir Biotechnology (VIR) has a Return-on-Tangible-Equity of 36.69% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #509 out of 1198 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Vir Biotechnology's Return-on-Tangible-Equity too high?
Vir Biotechnology's current Return-on-Tangible-Equity is 36.69%. Based on the distribution chart, Vir Biotechnology ranks #509 out of 1198 companies in the Biotechnology industry, which is above the industry midpoint.
How does Vir Biotechnology's Return-on-Tangible-Equity compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #509 out of 1198 companies for Return-on-Tangible-Equity. This puts Vir Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Return-on-Tangible-Equity is 36.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.20, compared to a current price of $9.50 — trading 77.5% below its estimated fair value. The current Return-on-Tangible-Equity is 36.69%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current Return-on-Tangible-Equity is 36.69% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIR has been successfully added to your 
